BioTime changes name to Lineage Cell Therapeutics

WORKFLOW SOLUTIONS
PRODUCTS
See More S&P Global Solutions
CONTENT
PODCASTS
SEE ALL EPISODES
SECTOR-SPECIFIC INSIGHTS
More ways we can help
NEWS & RESEARCH TOPICS
See More
Featured Events
Webinar2024 Regulatory Reporting Horizon: what to expect and how to prepare
- 12/05/2023
- Live, Online
- 03:00 pm - 04:00 pm GMT | 10:00 am- 11:00 am EST
WebinarUnderstanding, Identifying, and Assessing Supplier Diversity
- 12/06/2023
- Live, Online
- 01:00 pm - 02:00 pm EST
Webinar2024 Regulatory Reporting Horizon: what to expect and how to prepare
- 12/05/2023
- Live, Online
- 03:00 pm - 04:00 pm GMT | 10:00 am- 11:00 am EST
PLATFORMS
OTHER PRODUCTS
- Research Online
- 451 Research
See All Product Logins

In This List

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

1 Aug, 2019

Author Annalee Armstrong
Theme Healthcare & Pharmaceuticals

BioTime Inc., a biotechnology company that focuses on developing therapies for unmet medical needs, is changing its name to Lineage Cell Therapeutics Inc.

The company's ticker will change to LCTX, effective the same day as the name change on Aug. 12, the company said July 31.

Alameda, Calif.-based BioTime said the change reflects its extensive cell therapy platform.